Blog

  • HIV-infected people in Spain can now donate organs for transplant

    HIV-infected people in Spain can now donate organs for transplant

    Tuesday, 8 July 2025, 11:42

    After almost 40 years, the ban on donor transplants from HIV-positive people in Spain has been lifted. The new regulation will allow donations from living or deceased patients to other people infected with the virus. The official state gazette (BOE) has published the law change, which establishes that this practice can be safely applied to fight the effects of the infection. With this, the Ministry of Health abolishes the 1987 ban.

    In addition to increasing the availability of organs, health minister Mónica García said that this initiative is “aimed at eliminating the social stigma attached to people with HIV”.

    According to the Ministry of Health, if the veto on organ donation from HIV-positive patients had not existed in the last decade, up to 165 transplants could have been carried out with organs and tissues donated by the 65 people with HIV who died without being given the chance to support this act of altruism. Every year, some 50 HIV-positive patients are on the waiting list for organ transplants in Spain. Until now, they could only receive organs and tissues from non-infected people.

    Transplants for HIV-positive patients have been performed in Spain since the first decade of this century, thanks to new treatments that have made it possible to control and manage the disease. Today, transplants of all types of organs are performed on HIV-infected patients. By December 2024, 311 kidney transplants, 510 liver transplants, 11 lung transplants, 10 heart transplants and one pancreas-kidney transplant had been recorded in Spain, demonstrating good results in the long term.

    Over the years, HIV patients who have received a transplant have experienced favourable recovery thanks to new antiretroviral treatments, which do not interact with the immunosuppressive therapy needed to prevent organ rejection, and to the change in the natural history of hepatitis C virus co-infection brought about by the use of direct-acting antivirals.

    A safe practice

    Organ transplantation among people with HIV is now also a safe practice. Evidence from studies in recent years shows that HIV-infected transplant patients experience similar results with organs from HIV-positive or negative donors, leading to the authorisation of these interventions in the US in 2024.

    With the repeal of the 1987 law, it will now be possible to carry out this type of intervention in Spain, “responding to a historical demand of the HIV-infected community and the professionals who provide them with healthcare so that these people can become organ donors, if they wish”.

    Continue Reading

  • Map of How Body Responds to Extreme Conditions Could Help to Spot Early Signs of Illness

    Map of How Body Responds to Extreme Conditions Could Help to Spot Early Signs of Illness

     

    Study participant at the University of Portsmouth’s Extreme Environment Labs. Credit: University of Portsmouth

    Peer-reviewed, experimental study / data analysis, humans

    What happens inside your body when you’re tired, out of breath, or oxygen-deprived? A new study by researchers at the University of Portsmouth and University College London (UCL) has mapped how different parts of the body communicate during stress, potentially paving the way for earlier illness diagnosis.

    The study, conducted on healthy volunteers, used a new approach which studies how different organs and body systems communicate with each other. When a person faces physiological stress, different parts of the body have to work together to adapt and keep us functioning. 

    This study used a brand new way to map how systems talk to each other, moment by moment, in real-time. Instead of just checking whether the heart rate or breathing rate goes up or down (which is what doctors typically do), this team mapped out how one body signal influences another – like which signal is giving the most instructions and which is doing the most listening.

    By analysing recorded signals from the body (such as heart rate, respiratory rate, blood oxygen saturation, and the concentration of exhaled oxygen and carbon dioxide), the team tracked the transfer of information between these systems under conditions of low oxygen (hypoxia), sleep deprivation, and physical moderate intensity exercise (cycling).

    The team used wearable sensors to monitor key physiological signals in 22 healthy volunteers during different stress scenarios at the University of Portsmouth’s Extreme Environment Labs. A face mask measured breathing gases, while a pulse oximeter tracked blood oxygen levels.

    Researchers monitor physiological signals while participant cycles in hypoxic state at the University of Portsmouth’s Extreme Environment Labs. Credit: University of Portsmouth

    The study, published in the Journal of Physiology, is a continuation of earlier research that showed just 20 minutes of moderate exercise can improve brain performance after a bad night’s sleep.

    “This time, we wanted to understand how physiological stressors affect the body together, not just on their own,” said Dr Joe Costello, from the University’s School of Psychology, Sport and Health Sciences.

    “This approach lets us see how the body’s internal systems communicate with each other when they’re pushed to respond and adapt. And that kind of insight could be a game-changer for spotting when something starts to go wrong.”

    The unique method of monitoring these body signals is called ‘transfer entropy’. The result was a complex network of maps that show which body parts act as ‘information hubs’ under different stress conditions.

    Dr Costello explained: “What makes our approach so unique is that it doesn’t pigeonhole our data into one system or variable – it looks at how everything is connected in real time. Rather than just measuring a heart rate or a breathing rate on its own, it helps us understand the dynamic relationships between them. It’s a whole-body approach to human physiology, and that’s crucial if we want to see the bigger picture.”

    The team discovered that different stresses cause different parts of the body to take the lead in managing the situation:

    • During exercise, your heart becomes the main responder. It receives the most input from other systems because it’s working hard to pump blood to your muscles.

    • During low oxygen, it’s your blood oxygen levels that become the central player, working closely with breathing to adjust to the lack of air.

    • When sleep deprivation is added, the changes are more subtle – but if low oxygen is also involved, your breathing rate suddenly steps up and takes the lead.

    These information maps show early, hidden signs of stress that wouldn’t be obvious just by looking at heart rate or oxygen levels alone. That means this could one day help spot health problems before symptoms appear.

    Network mapping based on flow of information transfer between seven physiological variables

    Associate Professor Alireza Mani, head of the Network Physiology Lab at UCL, said: “These maps show that our body isn’t just reacting to one thing at a time. It’s responding in an integrated, intelligent way. And by mapping this, we’re learning what normal patterns look like, so we can start spotting when things go wrong.

    “This matters in healthcare because early signs of deterioration, especially in intensive care units or during the onset of complex conditions like sepsis or COVID-19, often show up not in the average numbers, but in the way those numbers relate to each other.”

    Dr Thomas Williams from the University of Portsmouth’’s School of Psychology, Sport and Health Sciences, added: “Extreme environments give us a safe and controlled way to replicate the kinds of physiological stress seen in illness or injury. By studying how the body responds and adapts under these conditions, we can begin to develop tools to detect early warning signs – often before symptoms appear – in clinical, athletic, and occupational settings.”

    With further investigation, the researchers hope the method could one day help doctors identify early warning signs of illness or poor recovery, especially in settings like intensive care, where vital signs are already being monitored. It could also be useful for athletes, military personnel, and people working in extreme environments.

    The paper encourages more scientists to take a “whole-body” view of physiology rather than focusing on isolated measurements. 

    It also recognises only healthy, young people were included in this study, and several individuals were withdrawn due to adverse events. The paper recommends further investigation into the relationship between physiological stressors and the body, with a broader mix of participants.

    ENDS

    Notes to Editors

    The study, Non-invasive assessment of integrated cardiorespiratory network dynamics after physiological stress in humans, is available here: https://physoc.onlinelibrary.wiley.com/doi/10.1113/JP288939

    DOI: 10.1101/2025.03.17.643643

    Filming opportunities at the University of Portsmouth’s Extreme Environment Labs are available. The research team will be able to replicate some of the study conditions, such as someone cycling on a bike in a hypoxic environment. 

    Available interviews:

    • Dr Joe Costello, from the University’s School of Psychology, Sport and Health Sciences

    • Associate Professor Alireza Mani, head of the Network Physiology Lab at UCL

    For more information contact:

    Robyn Austin-Montague, PR and Media Manager, University of Portsmouth, Tel: 0798 0419979, Email: [email protected]

    About the University of Portsmouth

    • The University of Portsmouth is a progressive and dynamic university with an outstanding reputation for innovative teaching, outstanding learning outcomes and globally significant research and innovation.

    • We were awarded the highest overall rating of Gold in the most recent Teaching Excellence Framework, one of only 27 Gold rated universities in England and one of five Gold rated universities in the South East. We’re proud to be one of the UK’s top 50 universities (with a 5-star rating) in the QS World University Rankings and one of the top 10 Young Universities in the UK based on Times Higher Education Young University rankings.

    • Our world-class research is validated by our impressive Research Excellence Framework (REF) outcomes where Portsmouth was ranked third of all modern UK universities for research power in the Times Higher Education REF rankings.

    port.ac.uk | Follow the University of Portsmouth on LinkedIn | Read news at port.ac.uk/news-events-and-blogs/news | Listen to the UoP Life Solved podcast on Acast | Find out what’s on at port.ac.uk/news-events-and-blogs/events


    Continue Reading

  • Au@Pt@HP1-HP2@Fe3O4 nanoenzymatic complexes based on CHA signal amplif

    Au@Pt@HP1-HP2@Fe3O4 nanoenzymatic complexes based on CHA signal amplif

    Xiaoyong Wang,1,* Jinxin Sheng,1,* Haifan Yang,2,3 Kang Shen,2,3 Jie Yao,1 Yayun Qian,2,3 Gaoyang Chen4

    1Department of General Surgery, Nantong Haimen People’s Hospital, Nantong, Jiangsu, People’s Republic of China; 2Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu, People’s Republic of China; 3The Key Laboratory of Syndrome Differentiation and Treatment of Gastric Cancer of the State Administration of Traditional Chinese Medicine, Yangzhou, Jiangsu, People’s Republic of China; 4Department of Oncology, The Affiliated Taizhou Second People’s Hospital of Yangzhou University, Taizhou, Jiangsu, People’s Republic of China

    Correspondence: Gaoyang Chen, Department of Oncology, The Affiliated Taizhou Second People’s Hospital of Yangzhou University, Taizhou, Jiangsu, People’s Republic of China, Email [email protected]

    Purpose: Early diagnosis of liver cancer requires highly sensitive detection of biomarkers. This study aims to develop a novel method for detecting circulating tumor DNA (ctDNA) in the serum of liver cancer patients, leveraging a catalytic hairpin self-assembly (CHA) signal amplification strategy combined with surface-enhanced Raman scattering (SERS) technology and nano-enzyme catalysis.
    Methods: We synthesized Au@Pt@HP1-HP2@Fe3O4 nano-enzyme complexes, utilizing the SERS-enhancing properties of Pt-coated Au nanoparticles (Au@Pt) and the separation-enrichment capability of Fe3O4 magnetic beads. The complexes catalyzed the oxidation of colorless TMB by H2O2 to produce blue ox-TMB, enabling quantitative detection of PIK3CA E542K mutant ctDNA. The assay’s performance was validated using gold standard qRT-PCR.
    Results: Under optimized conditions, the method achieved a detection limit for PIK3CA E542K as low as 4.12 aM. The assay demonstrated high sensitivity, specificity, and efficient magnetic separation, making it a robust tool for ctDNA detection.
    Conclusion: This study presents a highly sensitive and specific detection platform for liver cancer early diagnosis, characterized by magnetic separation and nano-enzyme catalysis. The method holds significant clinical potential for the accurate and early detection of liver cancer biomarkers.

    Keywords: surface-enhanced Raman scattering, nano-enzymes, circulating tumor DNA, liver cancer, catalytic hairpin self-assembly

    Introduction

    Liver cancer is a highly aggressive malignancy with a poor prognosis, primarily attributable to the absence of early symptoms and frequent late-stage diagnosis.1,2 As a real-time indicator of tumor genetic alterations and progression, circulating tumor DNA (ctDNA) has demonstrated significant value in early cancer detection. Studies reveal markedly elevated ctDNA levels in liver cancer patients, with its short half-life enabling dynamic tumor monitoring, making it an ideal diagnostic marker.3 Notably, PIK3CA gene mutations drive hepatocarcinogenesis by activating the PI3K/AKT/mTOR pathway, establishing this gene as a critical target for diagnosis and personalized therapy.4–6 However, conventional detection methods exhibit significant limitations. Real-time quantitative PCR (qPCR) has restricted applicability for minimal residual disease (MRD) monitoring. Droplet digital PCR (ddPCR) lacks standardized detection protocols and requires interpretation alongside multiparameter flow cytometry (MFC) data, and next-generation sequencing (NGS) demands sophisticated bioinformatics tools that are unavailable in most routine clinical laboratories.7,8 These constraints have accelerated the development of alternative diagnostic technologies, highlighting the urgent need for rapid and sensitive alternatives.9,10

    Surface Enhanced Raman Scattering (SERS), a highly sensitive spectroscopic analysis technique, has been widely used in biomedical detection in recent years.11–13 SERS can dramatically enhance Raman signals by adsorbing target analytes onto nanostructured noble metal surfaces, enabling highly sensitive detection of biomolecules even at trace concentrations.14–16 The latest clinical validation study confirms that SERS technology has significant advantages in the early diagnosis of liver cancer.17,18 Multiple hepatocellular carcinoma biomarkers miRNA122 and miRNA233 based on asymmetric competitive CRISPR (acCRISPR) and surface-enhanced Raman spectroscopy coupled to PTS with LODs of 10.36 and 4.65 fM, respectively.19 In addition, the SERS platform has a detection limit of 952 aM translation for liver cancer-associated long chain non-coding RNA (lncRNA).20 Nevertheless, these approach still face limitations, including suboptimal sensitivity or inadequate target specificity, which may restrict its clinical applicability.

    In recent years, the innovative design of nanomaterials has reinvigorated the development of biosensing technology.21–23 Nano-enzymes, as a kind of nanomaterials with enzyme-like catalytic activity, show great potential for application in the field of biosensing. Compared with natural enzymes, nano-enzymes not only have similar high catalytic activity, but also have the advantages of good stability, low cost and easy modification.24–27 Integrating nano-enzymes with SERS technology enables multiplexed signal amplification of target molecules. The catalytic activity of nano-enzymes synergistically enhances the signal intensity of the reaction system, substantially improving detection sensitivity and specificity.28,29 This combination not only extends the utility of SERS in analytical applications but also introduces an innovative paradigm for ultrasensitive bioanalysis in challenging sample environments. Pt-coated Au nanoparticles (Au@Pt) are ideal materials for SERS detection due to their excellent stability and enhancement effects. The Au@Pt not only inherits the excellent SERS enhancement properties of gold nanomaterials, but also further improves the catalytic activity and chemical stability of the material through the introduction of platinum.30–32 This unique structure enables the Au@Pt nanomaterials to simultaneously exert the surface plasmon resonance effect and the catalytic effect of the nano-enzymes in SERS detection,33,34 thus realizing dual signal amplification. In addition, magnetic beads, as an efficient separation and enrichment tool, can realize efficient capture and enrichment of low-abundance ctDNA in complex biological samples through specific binding to target molecules.35 The integration of magnetic beads with Au@Pt nanomaterials enhances both the capture efficiency of target molecules and the sensitivity and accuracy of SERS-based detection.

    Furthermore, DNA hairpin-based self-assembly has emerged as a prominent nucleic acid amplification strategy due to its operational simplicity and mild reaction requirements.36,37 The catalytic hairpin self-assembly (CHA) reaction, as a non-enzymatic signal amplification method, is capable of signal amplification by constructing a target strand cycling loop at room temperature.38,39 Combining the CHA reaction with SERS technology and nano-enzymes is expected to construct a novel and highly sensitive ctDNA detection platform for liver cancer.40

    In this study, we developed a CHA-based signal amplification system using synthesized Au@Pt@HP1-HP2@Fe3O4 nanozymes for ultrasensitive detection of ctDNA in liver cancer patient serum. As shown in Scheme 1, hairpin DNA1 (HP1) was modified on the surface of platinum-coated gold nanoparticles (Au@Pt) to prepare Au@Pt@HP1. Hairpin DNA2 (HP2) was modified on the surface of Fe3O4 to prepare HP2@ Fe3O4. PIK3CA E542K, as a target, can open its corresponding HP1 by complementary pairing, and HP2 replaces the target to form a large number of HP1-HP2 double-stranded structures, while the replaced ctDNA will continue to participate in the next round of CHA reaction. As the reaction cycle proceeds, more Au@Pt@HP1-HP2@Fe3O4 complex structures are formed with magnetic separation, enzyme-like catalytic activity and SERS-enhancing effect. The complex facilitated the oxidation of colorless TMB by H2O2, producing blue ox-TMB. Quantitative detection of PIK3CA E542K was accomplished by establishing a linear correlation between the SERS signal intensity at ox-TMB’s characteristic peak and the logarithmic concentration of the target ctDNA.

    Materials and Methods

    Materials

    HAuCl4 (≥99.9%), H2PtCl6 (≥99.9%) were purchased from Sinopharm Chemical Reagent Co., Ltd. (China), trisodium citrate (≥99.0%), iron oxide (Fe3O4, ≥90%), acetic acid-sodium acetate buffer (ACS grade), phosphate buffered saline (PBS, molecular biology grade), ethanol (EtOH, ≥99.7%), and 3,3′,5,5′-tetramethylbenzidine (TMB, ≥99%) were purchased from Bioengineering Biotechnology (Shanghai) Co. and used without further purification. The nucleotide sequences were custom-synthesized by Suzhou GeneWise Biotechnology Co. as shown in Table 1, and all experiments were conducted using deionized water with a resistivity exceeding 18.3 MΩ·cm.

    Table 1 Nucleotide Sequences Used in the Experiment

    Samples Collection and Processing

    Serum samples were collected from 30 healthy volunteers and 30 liver cancer patients at the Affiliated Taizhou Second People’s Hospital of Yangzhou University. The study protocol received ethical approval from the hospital’s Institutional Review Board, and all participants provided written informed consent in compliance with the Declaration of Helsinki guidelines. Following collection, blood samples were immediately centrifuged (12,000 rpm, 10 min, 4°C) to isolate serum, which was subsequently aliquoted and stored at −80 °C until analysis. Table 2 summarizes the demographic and clinical characteristics of all study participants.

    Table 2 Statistics of Sample Provider Information

    Synthesis of Platinum-Coated Gold (Au@Pt) and Preparation of Au@Pt@HP1

    First, the Au@Pt core-shell NPs were prepared by following a typical procedure with minor modifications.41 In this strategy, Au NPs were synthesized as the core. The aqueous HAuCl4 solution (0.5 mL, 1.0 wt.%) and ultrapure water (50.0 mL) were mixed. Trisodium citrate solution (0.8 mL, 1.0 wt.%) was rapidly injected into the boiling mixture. After the mixture was stirred for 10 min under boiling, ascorbic acid (1.0 mL, 0.1 M) and aqueous H2PtCl6 solution (1.25 mL, 1.0 wt.%) were introduced successively and were boiled for 25 min. The final solution changed from wine-red to brownish-black. The cooled mixture was washed three times by centrifugation at 10000 rpm/min. The Au@Pt was redispersed into ultrapure water and stored at 4 °C until use.

    To prepare Au@Pt@HP1, fresh TECP buffer (160 μL, 1 mM) was used to activate H1 (0.1 mM) on Au@Pt through a 12-hour reaction. The mixture was then dispersed in 80 μL of BSA solution (1 wt%) and incubated for 60 minutes, followed by purification at 9000 RPM for 25 minutes. This process yielded the final Au@Pt@HP1 complex.

    Synthesis of HP2@Fe3O4

    The capture probe was synthesized by modifying HP on the surface of Fe3O4. First, 500 mL of Fe3O4 (0.5 mg/mL) was measured in a test tube, and a magnet was placed at the bottom of the outer surface of the test tube after tilting the tube. 470 mL of PBS solution (10 mM) was added and the above steps were repeated several times after removing the supernatant. The carboxyl groups on the surface of MBs were activated with EDC (5 mL, 0.1 M) and NHS (5 mL, 0.1 M) at room temperature and incubated with shaking (500 rpm, 30 min). A drop of 10 mL of BSA solution (10 wt%) was added to seal the surface sites of Fe3O4. After rinsing with PBS, Fe3O4 was mixed with 470 mL of PBS solution, then TECP-activated HP2 was added and incubated for 12 hours. After repeated washing, the mixture was dispersed in PBS buffer to obtain HP2@Fe3O4.

    Optimal Peroxidase-Like Activity of Au@Pt@HP1-HP2@Fe3O4 Under Various Reaction Conditions

    To optimize the experimental conditions, the effects of reaction time, pH, TMB concentration, and H2O2 concentration on the SERS signal were systematically investigated. The influence of reaction time was studied by incubating a mixture of 40 mM TMB (40 μL), 10 M H2O2 (100 μL), and Au@Pt@HP1-HP2@Fe₃O₄ (100 μL) in a pH 4.0 buffer (1770 μL) for 0 to 20 minutes, followed by SERS spectra collection of the catalytic product oxTMB. The pH dependence was evaluated by adjusting the buffer pH from 3.0 to 8.0 while maintaining the same reactant concentrations and a 15-minute incubation period. For TMB concentration optimization, TMB solutions ranging from 0.5 to 1.0 mM were prepared in ethanol, mixed with 10 M H2O2 (100 μL) and Au@Pt@HP1@HP2@Fe₃O₄ (100 μL) in pH 4.0 buffer (1770 μL), and incubated for 15 minutes before SERS measurement. Similarly, the effect of H2O2 concentration was examined by varying its concentration from 0.1 to 0.8 mM in the reaction mixture, followed by a 15-minute incubation and SERS spectra acquisition. All SERS spectra of oxTMB were collected using a Raman spectrometer.

    SERS Signal Acquisition

    The SERS spectra of catalytic product oxTMB were collected using Raman spectrometer after incubation of 100 μL of freshly prepared H2O2 solution (10 M), 40 mM TMB solution (40 μL), and 100 μL of Au@Pt@HP1-HP2@Fe3O4 in acetic acid-sodium acetate buffer (1770 μL) at pH 4.0 for 15 min.

    Measurements and Characterization Techniques

    The main instruments used in the experiment included scanning electron microscopy (SEM, Hitachi S-4800), transmission electron microscopy (TEM, Philips Tecnai 12), field emission transmission electron microscopy (FE-TEM, FEI Tecnai G2 F30 S-TWIN), UV-Vis spectrophotometer (Cary 5000, Varian), and Raman spectrometer (Renishaw inVia Raman). Microscope). These instruments are used to characterize the morphology and structure of nanomaterials, as well as to perform SERS spectroscopy measurements and analysis. Raman spectra were obtained using a Renishaw inVia microscope with a 5 mW laser. SERS measurements were performed at 785 nm using a 50× objective, with a fixed exposure time of 10s for all experiments.

    Results and Discussions

    To systematically validate the proposed CHA-nanozyme-SERS integrated strategy (as illustrated in Scheme 1), the experimental results are presented through three hierarchical levels: (1) At the material characterization level, TEM, EDX and etc. analyses confirm the precise assembly of Au@Pt@HP1-HP2@Fe3O4; (2) At the molecular mechanism level, gel electrophoresis and enzyme kinetics verify the synergistic effects between CHA cycling and nanozyme catalysis; (3) At the clinical application level, the high concordance between serum tests from 30 liver cancer patients and qPCR results confirms the method’s reliability. This progressive demonstration directly addresses the two key challenges raised in the Introduction: the sensitivity (LOD=4.12 aM) and specificity of ctDNA detection.

    Scheme 1 Schematic representation of the detection principle and process.

    Characterization of Au@Pt@HP1-HP2@Fe3O4

    Figure 1A demonstrates that the synthesized Au@Pt nanoparticles exhibit uniform spherical morphology with an average diameter of 55 nm. SEM characterization (Figure 1B) reveals the Fe3O4 microspheres display well-defined spherical structures (200 nm diameter) with excellent size uniformity. This morphological consistency enabled the successful preparation of stable Au@Pt@HP1-HP2@Fe3O4 nanocomposites with controlled particle size distribution. The composite structure Au@Pt@HP1 was observed. Au@Pt was homogeneously dispersed on the surface of HP2@Fe3O4 with uniform morphology, structural integrity, and good dispersion, which had an extremely strong SERS enhancement effect (Figure 1C–F). HRTEM images of the Au@Pt@HP1 surface showing clear lattice fringes with a layer spacing of 0.24 nm corresponding to the {111} facets of Au and Pt are shown in Figure 2G. The SAED patterns of Au@Pt@HP1-HP2@Fe3O4 are shown in Figure 2H. The characteristic peak intensity of TMB at 1607 cm−1 was selected to study the SERS enhancement effect of Au@Pt@HP1-HP2@Fe3O4. As shown in Figure 2I, free TMB (1 mM) exhibited only baseline Raman signals, whereas the TMB@Au@Pt@HP1-HP2@Fe3O4 complex at 1 nM concentration generated intense characteristic peaks with significant signal enhancement. This dramatic improvement in SERS response demonstrates the excellent plasmonic activity of our Au@Pt@HP1-HP2@Fe3O4 nanocomposite system.

    Figure 1 Structural characterization diagrams of Au@Pt, Fe3O4 and Au@Pt@HP1@HP2@Fe3O4. (A) TEM images of Au@Pt and (B) SEM Fe3O4. (C and D) SEM and (E and F) TEM images of Au@Pt@HP1@HP2@Fe3O4. (G and H) HRTEM images and (I) SERS spectra of pure TMB and TMB+ Au@Pt@HP1@HP2@Fe3O4.

    Figure 2 Elemental analysis diagram for Au@Pt@HP1@HP2@Fe3O4. (A) HAADF-STEM images of Au@Pt@HP1-HP2@Fe3O4. (B–E) elemental mappings of Au@Pt@HP1-HP2@Fe3O4. (F) EDX spectra of the Au@Pt@HP1-HP2@Fe3O4.

    The HAADF-STEM image in Figure 2A clearly shows the structure of Au@Pt@HP1-HP2@Fe3O4. Figure 2B–E forms composite Au (blue), Fe (orange), Pt (green) and O (red) elemental maps to further show the specific elemental arrangement of Au@Pt@HP1-HP2@Fe3O4 and its structure. Platinum is densely coated on the surface of the gold particles in the form of granules. Figure 2F shows the EDX spectrum of Au@Pt@HP1-HP2@Fe3O4, which reveals that the complex contains the elements Au, Pt, Fe, and O. Among them, Au and Pt are composed of Au@Pt, Fe and O are mainly from Fe3O4, while the Cu peak is caused by the copper mesh that carries the sample.

    Evaluation of CHA Reaction

    To validate the CHA reaction for ctDNA detection and assess its performance, we conducted gel electrophoresis analysis using PIK3CA E542K as the model target (Figure 3). In lane 5, the appearance of HP1-HP2 was observed in the presence of PIK3CA E542K along with HP1 and HP2. Formation of the HP1-PIK3CA E542K product and release of the target strand were clearly observed when PIK3CA E542K and HP1 were placed in lane 6. The above experimental results indicate that CHA reactions were successfully performed in this study.

    Figure 3 Validation of CHA reactions by gel electrophoresis. Lane 1: Marker; Lane 2: PIK3CA E542K; Lane 3: HP1; Lane 4: HP1+HP2; Lane 5: HP1+HP2+PIK3CA E542K; Lane 6: HP1+PIK3CA E542K.

    Experimental Optimization

    Reaction conditions play a crucial role in the activity of Au@Pt@HP1-HP2@Fe3O4. Usually, the influencing factors of enzymatic reaction include temperature, pH and substrate concentration. Firstly, the effect of reaction time was investigated, as shown in Figure 4A. With the increase of time, the Raman characteristic peak intensity of ox-TMB at 1607 cm−1 gradually increased, and basically stopped changing after 15 min, Due to the instability of the oxTMB signal, the SERS signal gradually weakened after 15 min.42,43 Therefore, the optimal reaction time was set at 15 min. The effect of pH on the SERS signals was shown in Figure 4B. The peroxidase-like activity of Au@Pt@HP1-HP2@Fe₃O₄ nanocomposites exhibited strong pH dependence in the H2O2-TMB system. Quantitative SERS analysis revealed optimal catalytic performance at pH 4.0, with signal intensity increasing progressively from pH 3 to 4, then decreasing significantly across the pH 5–8 range. This pH-activity profile aligns with established literature reports demonstrating accelerated TMB oxidation kinetics in weakly acidic conditions (pH 3–5) compared to neutral or alkaline environments.44,45 By analyzing the effect of H2O2 concentration on the catalytic activity of Au@Pt@HP1-HP2@Fe3O4, the results are shown in Figure 4C. The relative activity of H2O2 concentration in the range of 0.1–0.5 mM showed an increasing trend, whereas it began to decrease at a concentration greater than 0.5 mM.46 It indicates that the catalytic activity has reached saturation at H2O2 concentration of 0.5 mM. In order to determine the effect of the concentration of TMB on the reaction, the concentration of TMB was investigated in the range of 0.5 to 1.0 mM. The results are shown in Figure 4D. The SERS signal reached its highest value at a TMB concentration of 0.8 mM. This is mainly due to the poor solubility of TMB in aqueous solution.47 Therefore, 0.8 mM was chosen as the optimal concentration. In summary, the optimal reaction time, pH, TMB concentration and H2O2 concentration were 15 min, 4, 0.8 mM and 0.5 mM, respectively.

    Figure 4 Optimization of H2O2 detection using Au@Pt@HP1-HP2@Fe3O4 in the presence of TMB. (A) Incubation time, (B) solution pH, (C) H2O2 concentration, (D) TMB concentration.

    Enzyme Catalytic Kinetics

    The peroxidase-mimetic activity of Pt@Au@HP1-HP2@Fe3O4was evaluated using the H2O2 -TMB catalytic system. Upon simultaneous addition of both H2O2 and Pt@Au@HP1-HP2@Fe3O4 to the TMB solution, an immediate color transition from colorless to blue was observed (Figure 5A), indicating rapid TMB oxidation. UV-vis spectroscopy confirmed this activity through the appearance of a characteristic absorption peak at 651 nm (Figure 5B), corresponding to the oxidized TMB product (oxTMB). These results unequivocally demonstrate the intrinsic peroxidase-like catalytic capability of the Pt@Au@HP1-HP2@Fe3O4 nanocomposite. The effect of different TMB concentrations on the catalytic reaction in the presence of Au@Pt@HP1-HP2@Fe3O4 was investigated. As shown in the Figure 5C, the absorbance increases with time at different TMB concentrations, and it is clear that the reaction speed increases with increasing TMB concentration. In addition, we evaluated the Michaelis-Menten kinetics of Au@Pt@HP1-HP2@Fe3O4 to gain further insight into its catalytic performance (Figure 5D). Compared with other reported nanozymes,48 Au@Pt@HP1-HP2@Fe3O4 exhibited a relatively lower Km (0.4089 mM) and higher Vmax (0.9533 μM/s), indicating that Au@Pt@HP1-HP2@Fe3O4 has desirable catalytic properties, It has a good affinity for the substrate.

    Figure 5 Characterization of the nanozyme-catalyzed TMB oxidation reaction. (A) Color of the different solutions in the presence and (B) UV−vis spectra of different reaction systems. (C) Plot of initial rate versus concentration of TMB. (D) Michaelis−Menten kinetic of Au@Pt@HP1-HP2@Fe3O4.

    Performance Evaluation

    The magnetic properties of the Au@Pt@HP1-HP2@Fe3O4 nanocomposites were systematically characterized to assess their applicability in SERS-based detection. When exposed to an external magnetic field, the composites were quickly drawn from the solution and aggregated, while the supernatant no longer catalyzed TMB (Figure 6A). This highlights the strong magnetic properties of Au@Pt@HP1-HP2@Fe3O4. The rapid magnetic separation capability simplifies washing and product isolation, enhancing assay efficiency and sensitivity. The system demonstrated excellent SERS signal reproducibility, with oxTMB exhibiting consistent Raman intensities (RSD = 4.1%) across multiple measurements (n=10) over 24 hours (Figure 6B and C). This remarkable stability highlights the robustness of the Au@Pt@HP1-HP2@Fe3O4 platform for quantitative analysis. To verify the homogeneity, SERS spectra of 10 randomly selected points on the same composite material were measured to evaluate uniformity (Figure S1). The results show that the peak intensities at all points are relatively consistent, and the relative standard deviation (RSD) at 1607 cm⁻¹ is 7.88% (Figure S2), indicating good homogeneity. Subsequently, five batches of composites were prepared at different times for the detection of PIK3CA E542K solution. The corresponding SERS spectra are shown in Figure 6D. It can be seen that the spectral waveforms are basically the same with almost no significant difference, and the RSD value of the SERS signal intensity of the characteristic peak at 1607 cm−1 is 4.26%, which demonstrates that the composite material has a good reproducibility and strengthens the confidence of the determination. In addition, the stability of the composite was explored. Over time, the SERS spectral profile showed no notable changes, with only a minor reduction in intensity. The signal stabilized after 6 days and maintained 91.72% of its original intensity even after 18 days (Figure 6E). This sustained signal demonstrates the composite’s long-term stability for assay applications. To evaluate the specificity, experiments included interference sequences such as a single-base mismatch (MT1), a three-base mismatch (MT3), and a random sequence. As shown in Figure 6F, the I1607/I1183 ratio of PIK3CA E542K is much larger than the signal intensity of the interfering sequences, which is the result of the specific binding of HP1 to PIK3CA E542K.

    Figure 6 Performance Evaluation. (A) Photographs of Au@Pt@HP1-HP2@Fe3O4 in a vessel without (left) and with (right) an external magnetic field; (B) Raman intensities of oxTMB at different time intervals (each spectrum in the same time period is the average of 10 acquisitions; (C) Consistency of Raman spectra of oxTMB at 1607 cm−1 wavelength for different time intervals within 60 min; (D) SERS spectra corresponding to different batches of SERS microfluidic chips; (E) line graphs of peak intensity at 1607 cm−1 after different storage times; (F) histograms corresponding to the ratio of peak intensities at 1183 cm−1 and 1607 cm−1 for specificity tests. Errors were calculated based on the standard deviation of three measurements.

    Quantitative Testing

    The assay’s sensitivity is vital for detecting low-abundance biomarkers, particularly in early-stage cancer diagnosis. To evaluate this, varying concentrations of PIK3CA E542K were spiked into serum samples, and the SERS signals were analyzed (Figure 7A). The results revealed a gradual decline in SERS intensity as the concentration increased. A strong linear correlation was observed between the logarithm of PIK3CA E542K concentration and the peak intensity at 1607 cm⁻¹, described by the equation: y = 4985.19x – 2821.85 (R² = 0.9928) (Figure 7B). The LOD was calculated based on the characteristic peaks of the SERS spectra using the following equation: where a and b were the variables obtained with a linear regression of the signal-concentration curve, SD was the standard deviation and Cblank is the SERS intensity of the blank sample.49 The detection limit of PIK3CA E542K was calculated to be 4.12 aM. This sensitivity places the proposed SERS microfluidic chip among the most advanced methods currently available (Table 3).

    Table 3 Comparison of the Proposed Method with Currently Reported Methods

    Figure 7 Quantitative analysis. (A) SERS spectra of different concentrations of PIK3CA E542K in serum; (B) linear relationship between the SERS signal intensity at 1607 cm−1 and the logarithm of PIK3CA E542K concentration.

    Characterization of Clinical Samples

    Magnetic resonance imaging (MRI) can provide multi-parameter, multi-sequence, and multi-directional images to evaluate the extent of liver cancer lesions. Due to its excellent contrast resolution for liver tissue, MRI can accurately and meticulously display the anatomical structure of the liver and its pathological features. Axial plane images can clearly demonstrate the characteristics of liver cancer (Figure 8A–C and 8E–G). On non-contrast T1-weighted sequences, liver cancer typically appears as hypointense or isointense, while on post-contrast scans, it shows significant enhancement in the arterial phase and a “wash-in and wash-out” pattern in the portal venous phase. Coronal plane images can clearly reveal the size, boundaries of the tumor, and its invasion into surrounding tissues or blood vessels (Figure 8D and H). The diagnosis of liver cancer primarily relies on pathological examination. Figure 8I–K shows pathological images of liver cancer, where disordered arrangement of tumor cells can be observed, with large and irregular nuclei, reduced cytoplasm, prominent nucleoli, and areas of necrosis or hemorrhage in some regions. The markedly abnormal cells exhibit an increased nuclear-to-cytoplasmic ratio, unclear intercellular connections, and areas of fibrous tissue hyperplasia or inflammatory cell infiltration.

    Figure 8 Pathologic findings in patients with liver cancer. (AH) MRI images of two patients with liver cancer. (IK) Pathological HE staining of liver cancer tissues.

    Real Sample Analysis

    To further test the reliability and accuracy of this SERS microfluidic chip in the analysis of clinical samples, it was utilized to detect the expression levels of PIK3CA E542K in serum samples from 30 healthy subjects and 30 liver cancer patients. The obtained spectra were processed to obtain the average spectra (Figure 9A), corresponding to the SERS signal intensities at 1607 cm−1 as shown in Figure 9B. It can be seen that the expression level of PIK3CA E542K was significantly elevated in the serum of liver cancer patients compared with that of healthy subjects. After that, the SERS signal intensity at 1607 cm−1 in the SERS spectrum was substituted into the linear regression equation to calculate the expression level of PIK3CA E542K. The accuracy of this assay was verified by comparing the results with those of the qRT-PCR assay (Table 4). The results showed that the assay was highly consistent with the results of qRT-PCR assay and had good detection accuracy.

    Table 4 The Results of SERS and qRT-PCR for Clinical Samples

    Figure 9 Plot of clinical samples tested by this method and comparison with qRT-PCR assay. (A) Average SERS spectra of sera from healthy subjects and liver cancer patients and (B) histograms of SERS signal intensity at the characteristic peaks of 1607 cm−1.

    Conclusion

    In this study, a highly sensitive method for the detection of ctDNA in the serum of liver cancer patients was successfully developed based on the CHA signal amplification strategy using the synthesized Au@Pt@HP1-HP2@Fe3O4 nano-enzyme complex. By modifying HP1 on the surface of Au@Pt and (HP2 with Fe3O4 magnetic beads, a multifunctional detection platform with magnetic separation, catalytic activity of the nano-enzymes, and SERS-enhanced effect was constructed. PIK3CA E542K was used as a target, and complementary pairing of HP1 and HP2 was triggered by CHA reaction. A large number of HP1-HP2 double-stranded structures were formed, while the released ctDNA continued to participate in the next round of cyclic reaction to achieve signal amplification. In comparison with existing detection technologies, we have for the first time organically integrated three techniques: catalytic hairpin assembly (CHA) cyclic amplification, gold-platinum nanozyme catalysis, and magnetic aggregation-based surface-enhanced Raman scattering (SERS), to construct a novel nanozyme-SERS detection platform that achieves multilevel signal amplification. The complex catalyzed the oxidation of colorless TMB by H2O2 to generate blue ox-TMB. A linear relationship between ctDNA concentration and signal intensity was established by detecting the signal intensity of the SERS characteristic peak of ox-TMB. The results showed that the detection limit of this method for PIK3CA E542K was as low as 4.12 aM, 2 orders of magnitude improvement over existing detection technologies. The assay can be completed in just 15 minutes, much faster than the hour-long cycle time of conventional sequencing methods. In addition, the platform exhibits excellent reproducibility, stability and specificity. Analysis of the clinical samples showed that the expression level of PIK3CA E542K in the serum of liver cancer patients was significantly higher than that of healthy subjects, and the detection results were highly consistent with qRT-PCR. In conclusion, the SERS microfluidic chip developed in this study combined with the CHA signal amplification strategy can efficiently and accurately determine the expression level of ctDNA, which provides a new technical means for the early diagnosis of liver cancer, and has an important potential for clinical application.

    Acknowledgments

    This study was financially supported by grants from the Social Development Foundation of Taizhou (TS202225); and the Key Research Institute of State Administration of Traditional Chinese Medicine (202259); General Program of Nantong Municipal Health Commission Research Project (MS2024111, MS2024112); Nantong University Special Research Fund for Clinical Medicine (2024LZ028).

    Disclosure

    There are no conflicts of interest in this study to declare.

    References

    1. Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873(1):188314. doi:10.1016/j.bbcan.2019.188314

    2. Yao Y, Hu Y, Meng X, et al. Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma. Pharm Sci Adv. 2024;2:100046. doi:10.1016/j.pscia.2024.100046

    3. Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019;18(1):114. doi:10.1186/s12943-019-1043-x

    4. Nault JC, Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin Liver Dis. 2011;31(2):173–187. doi:10.1055/s-0031-1276646

    5. Yang S, Qian L, Li Z, et al. Integrated multi-omics landscape of liver metastases. Gastroenterology. 2023;164(3):407–423.e417. doi:10.1053/j.gastro.2022.11.029

    6. Zhang A, Lakshmanan J, Motameni A, Harbrecht BG. MicroRNA-203 suppresses proliferation in liver cancer associated with PIK3CA, p38 MAPK, c-Jun, and GSK3 signaling. Mol Cell Biochem. 2018;441(1–2):89–98. doi:10.1007/s11010-017-3176-9

    7. Kalil JA, Krzywon L, Petrillo SK, et al. Feasibility of ctDNA in detecting minimal residual disease and predicting recurrence for colorectal cancer liver metastases. Front Oncol. 2024;14:1418696. doi:10.3389/fonc.2024.1418696

    8. Sun Y, Kong X, Yu J, et al. Characterization of genomic clones by targeted deep sequencing of ctDNA to monitor liver cancer. Transl Cancer Res. 2021;10(10):4387–4402. doi:10.21037/tcr-21-1005

    9. Zhang L, Chen J, He M, Su X. Molecular dynamics simulation-guided toehold mediated strand displacement probe for single-nucleotide variants detection. Exploration. 2022;2(1):20210265. doi:10.1002/EXP.20210265

    10. Li R, Liu X, Chen J. Opportunities and challenges of hole transport materials for high-performance inverted hybrid-perovskite solar cells. Exploration. 2023;3(3):20220027. doi:10.1002/EXP.20220027

    11. Beeram R, Vepa KR, Soma VR. Recent trends in SERS-based plasmonic sensors for disease diagnostics, biomolecules detection, and machine learning techniques. Biosensors. 2023;13(3). doi:10.3390/bios13030328

    12. Liu H, Gao X, Xu C, Liu D. SERS tags for biomedical detection and bioimaging. Theranostics. 2022;12(4):1870–1903. doi:10.7150/thno.66859

    13. Lee S, Dang H, Moon JI, et al. SERS-based microdevices for use as in vitro diagnostic biosensors. Chem Soc Rev. 2024;53(11):5394–5427. doi:10.1039/d3cs01055d

    14. Kukkar D, Chhillar M, Kim KH. Application of SERS-based nanobiosensors to metabolite biomarkers of CKD. Biosens Bioelectron. 2023;232:115311. doi:10.1016/j.bios.2023.115311

    15. Huang Z, Peng J, Xu L, Liu P. Development and application of surface-enhanced Raman scattering (SERS). Nanomaterials. 2024;14(17):1417. doi:10.3390/nano14171417

    16. Andreiuk B, Nicolson F, Clark LM, et al. Design and synthesis of gold nanostars-based SERS nanotags for bioimaging applications. Nanotheranostics. 2022;6(1):10–30. doi:10.7150/ntno.61244

    17. Shin H, Choi BH, Shim O, et al. Single test-based diagnosis of multiple cancer types using exosome-SERS-AI for early stage cancers. Nat Commun. 2023;14(1):1644. doi:10.1038/s41467-023-37403-1

    18. Sun T, Lin Y, Yu Y, et al. Low-abundance proteins-based label-free SERS approach for high precision detection of liver cancer with different stages. Anal Chim Acta. 2024;1304:342518. doi:10.1016/j.aca.2024.342518

    19. Jiang H, Qian C, Deng Y, et al. Novel multimode assay based on asymmetrically competitive CRISPR and Raman barcode spectra for multiple hepatocellular carcinoma biomarkers detection. Anal Chem. 2024;96(50):20004–20014. doi:10.1021/acs.analchem.4c04593

    20. Tao H, Weng S, Xu L, et al. Target-triggered assembly of plasmon resonance nanostructures for quantitative detection of lncRNA in liver cancer cells via surface enhanced Raman spectroscopy. Biosens Bioelectron. 2024;261:116488. doi:10.1016/j.bios.2024.116488

    21. Ai Y, Tian Y, Qiao J, Wang C, Li H. “Yin-Yang philosophy” for the design of anticancer drug delivery nanoparticles. Biomater Transl. 2024;5(2):144–156. doi:10.12336/biomatertransl.2024.02.005

    22. Qi L, Zhao T, Yan J, et al. Advances in magnesium-containing bioceramics for bone repair. Biomater Transl. 2024;5(1):3–20. doi:10.12336/biomatertransl.2024.01.002

    23. Jia G, Jiang Y, Li X. Targeted drug conjugates in cancer therapy: challenges and opportunities. Pharm Sci Adv. 2024;2:100048. doi:10.1016/j.pscia.2024.100048

    24. Ansari SA, Husain Q. Potential applications of enzymes immobilized on/in nano materials: a review. Biotechnol Adv. 2012;30(3):512–523. doi:10.1016/j.biotechadv.2011.09.005

    25. Ramya RK, Theraka K, Ramprasadh SV, et al. Pragmatic treatment strategies for polyaromatic hydrocarbon remediation and anti-biofouling from surfaces using nano-enzymes: a review. Appl Biochem Biotechnol. 2023;195(9):5479–5496. doi:10.1007/s12010-022-03848-1

    26. Jacob E, Mathew D, Benny L, Varghese A. Emerging nanomaterials as versatile nanozymes: a new dimension in biomedical research. Top Curr Chem. 2024;382(3):28. doi:10.1007/s41061-024-00473-w

    27. Li J, Cai X, Jiang P, et al. Co-based nanozymatic profiling: advances spanning chemistry, biomedical, and environmental sciences. Adv Mater. 2024;36(8):e2307337. doi:10.1002/adma.202307337

    28. Zhang T, Zhu S, Wang J, et al. Construction of a novel nano-enzyme for ultrasensitive glucose detection with surface-enhanced Raman scattering. Spectrochim Acta A Mol Biomol Spectrosc. 2023;291:122307. doi:10.1016/j.saa.2022.122307

    29. Yao D, Wen G, Gong L, Li C, Liang A, Jiang Z. A Highly Sensitive SERS and RRS Coupled Di-Mode Method for CO Detection Using Nanogolds as Catalysts and Bifunctional Probes. Nanomaterials. 2020;10(3):450. doi:10.3390/nano10030450

    30. Engelbrekt C, Šešelj N, Poreddy R, Riisager A, Ulstrup J, Zhang J. Atomically thin Pt shells on Au nanoparticle cores: facile synthesis and efficient synergetic catalysis. J Mater Chem A. 2016;4(9):3278–3286. doi:10.1039/C5TA08922K

    31. Zhang Y, Janyasupab M, Liu C-W, et al. Improvement of amperometric biosensor performance for H2O2 detection based on bimetallic PtM (M = Ru, Au, and Ir) nanoparticles. Int J Electrochem. 2012;2012(1):410846. doi:10.1155/2012/410846

    32. Lee J-W, Son J, Yoo K-M, Lo YM, Moon B. Characterization of the antioxidant activity of gold@platinum nanoparticles. RSC Adv. 2014;4(38):19824–19830. doi:10.1039/c4ra01765j

    33. He W, Liu Y, Yuan J, et al. Au@Pt nanostructures as oxidase and peroxidase mimetics for use in immunoassays. Biomaterials. 2011;32(4):1139–1147. doi:10.1016/j.biomaterials.2010.09.040

    34. Zhang B, Lv Y, Yu C, et al. Au-Pt nanozyme-based multifunctional hydrogel dressing for diabetic wound healing. Biomater Adv. 2022;137:212869. doi:10.1016/j.bioadv.2022.212869

    35. Pathania H, Chauhan P, Chaudhary V, et al. Engineering core-shell mesoporous silica and Fe(3)O(4)@Au nanosystems for targeted cancer therapeutics: a review. Biotechnol Genet Eng Rev. 2024;40(4):3653–3681. doi:10.1080/02648725.2022.2147685

    36. Abolhasan R, Mehdizadeh A, Rashidi MR, Aghebati-Maleki L, Yousefi M. Application of hairpin DNA-based biosensors with various signal amplification strategies in clinical diagnosis. Biosens Bioelectron. 2019;129:164–174. doi:10.1016/j.bios.2019.01.008

    37. Hua Y, Ma J, Li D, Wang R. DNA-based biosensors for the biochemical analysis: a review. Biosensors. 2022;12(3):183. doi:10.3390/bios12030183

    38. Xing C, Dai J, Huang Y, et al. Active self-assembly of train-shaped DNA nanostructures via catalytic hairpin assembly reactions. Small. 2019;15(27):e1901795. doi:10.1002/smll.201901795

    39. Bai Y, Xu P, Li S, et al. Signal amplification strategy of DNA self-assembled biosensor and typical applications in pathogenic microorganism detection. Talanta. 2024;272:125759. doi:10.1016/j.talanta.2024.125759

    40. Wang S, Guang J, Gao Y, et al. Fluorescent DNA tetrahedral probe with catalytic hairpin self-assembly reaction for imaging of miR-21 and miR-155 in living cells. Mikrochim Acta. 2024;191(8):462. doi:10.1007/s00604-024-06529-4

    41. Zhang M, Bu T, Bai F, et al. Gold nanoparticles-functionalized three-dimensional flower-like manganese dioxide: a high-sensitivity thermal analysis immunochromatographic sensor. Food Chem. 2021;341:128231. doi:10.1016/j.foodchem.2020.128231

    42. Josephy PD, Eling T, Mason RP. The horseradish peroxidase-catalyzed oxidation of 3,5,3’,5’-tetramethylbenzidine. Free radical and charge-transfer complex intermediates. J Biol Chem. 1982;257(7):3669–3675. doi:10.1016/S0021-9258(18)34832-4

    43. Wan J, Liu Q, Tang P, et al. SERS-based error calibration of a TMB-H(2)O(2) colorimetric system. Analyst. 2023;148(4):869–875. doi:10.1039/D2AN01914K

    44. Tang M, Ni J, Yue Z, et al. Polyoxometalate-nanozyme-integrated nanomotors (POMotors) for self-propulsion-promoted synergistic photothermal-catalytic tumor therapy. Angew Chem Int Ed Engl. 2024;63(6):e202315031. doi:10.1002/anie.202315031

    45. Yue Z, Li J, Tang M, Sun T, Chen C, Wu Z. Nanozyme-based clusterphene for enhanced electrically catalytic cancer therapy. Adv Healthc Mater. 2024;13(9):e2303222. doi:10.1002/adhm.202303222

    46. He W, Han X, Jia H, Cai J, Zhou Y, Zheng Z. AuPt alloy nanostructures with tunable composition and enzyme-like activities for colorimetric detection of bisulfide. Sci Rep. 2017;7:40103. doi:10.1038/srep40103

    47. Pham XH, Seong B, Bock S, et al. Nonenzymatic hydrogen peroxide detection using surface-enhanced Raman scattering of gold-silver core-shell-assembled silica nanostructures. Nanomaterials. 2021;11(10).

    48. Luo S, Liu Y, Rao H, Wang Y, Wang X. Fluorescence and magnetic nanocomposite Fe(3)O(4)@SiO(2)@Au MNPs as peroxidase mimetics for glucose detection. Anal Biochem. 2017;538:26–33. doi:10.1016/j.ab.2017.09.006

    49. Mukanova Z, Gudun K, Elemessova Z, Khamkhash L, Ralchenko E, Bukasov R. Detection of paracetamol in water and urea in artificial urine with gold nanoparticle@Al foil cost-efficient SERS substrate. Anal Sci. 2018;34(2):183–187. doi:10.2116/analsci.34.183

    50. Chen C, He R, Zhang Z, Chen Y. Dual-recognition-based determination of ctDNA via the clamping function of peptide nucleic acid and terminal protection of small-molecule-linked DNA. Analyst. 2020;145(23):7603–7608. doi:10.1039/D0AN01305F

    51. Wang K, Lin X, Zhang M, et al. ACEK biosensor for the minute-scale quantification of breast cancer ctDNA. Sensors. 2024;24(2).

    52. Sun Y, He S, Peng Y, Liu M, Xu D. A novel label-free capillary electrophoresis LED-induced fluorescence platform based on catalytic hairpin assembly for sensitive detection of multiple circulating tumor DNA. Analyst. 2024;149(5):1548–1556. doi:10.1039/D3AN01993D

    53. Uygun ZO, Yeniay L, Gi Rgi NSF. CRISPR-dCas9 powered impedimetric biosensor for label-free detection of circulating tumor DNAs. Anal Chim Acta. 2020;1121:35–41. doi:10.1016/j.aca.2020.04.009

    Continue Reading

  • Radio Replay: British GP Chequered Flag

    Radio Replay: British GP Chequered Flag

    There were mixed emotions for the team when the chequered flag flew at the 2025 British Grand Prix on Sunday.

    Alex Albon produced a last-lap moment to remember, pulling off a great around-the-outside overtake on Fernando Alonso at Copse to seal P8, having started P13.

    Carlos Sainz looked on course for more points at Silverstone, but contact from Charles Leclerc late on dropped him down the order with damage, ultimately finishing P12.

    After a hard-fought 52 laps in classic British weather, here’s how it sounded on the radio as both of our drivers reached the finish.

    Gulf Driven By Words

    Submit five words a day that encapsulate the moments, ambitions and memories that make Williams and Gulf special

    James Urwin (JU), Alex’s Race Engineer, was the first to react after that Copse move, with Team Principal James Vowles (JV) also jumping on to offer his thoughts.

    JU: Lovely stuff – P8, P8. Epic move.

    AA: Yes, yes! Well done, everyone.

    JV: Well done, Alex. Really tricky conditions all race long. I think there were moments where we just weren’t quick enough and then as it dried up it got into those grip conditions you were flying at the end, well done. Lots to learn but I’m looking forward to Spa where we take a step again.

    AA: Yep, well done James. I think we were struggling a bit there on the Inters, but it came alive on the slicks. Was Nico third?

    JU: He was, yeah. It’s a bit of a topsy-turvy order. Hulkenberg 3rd, Hamilton 4th, Verstappen 5th, Gasly 6th, Stroll 7th. He was 3.5s ahead of us. Another three or four laps and it would have been more interesting.

    AA: Yeah, well congrats to Nico – what a legend! That’s his first podium, isn’t it?

    JU: I believe so. Lovely job, well done. That was really good. Nice move on the last lap, similar to Turn 15 last year.

    Carlos and Gaetan chatting earlier in the British GP race weekend

    Gaetan Jego (GJ), Carlos’ Race Engineer, was by the Spaniard’s side through a frustrating finale, with James also chiming in to offer his support post-race.

    CS: Incredible. This year my luck is incredible.

    GJ: It was a good effort, nothing you could do. There was contact and quite a bit of loss

    CS: Yeah, but it’s tiring. There’s always something happening. It’s incredible.

    GJ: You know we’re building up to something, it’s OK.

    JV: Carlos, a really difficult race. Well done. Situations occur, they weren’t in your control. That was outside of it. I think my reflection is we had to park our pace at the end. That car was too damaged. We didn’t get it all right. Well done for persisting on this. I’m looking forward to the Spa where we move forward again to the field.

    CS: Yeah, no worries. It’s just I wish I had a bit more luck this year, but every time something happens.

    JV: Yeah, I feel the same way. Let’s come back stronger.

    CS: Some feedback on the pace at the end. There was good pace on the slicks, but a lot of learning. Some good learning for the next one in Belgium.

    Williams x Fresh Ego Kid:

    Continue Reading

  • Meet the drivers who are taking part in the 2025 Berlin Rookie Test

    Meet the drivers who are taking part in the 2025 Berlin Rookie Test

    Article by Katy Fairman

    Formula E returns to Germany this week for a double-header in Berlin, but once the racing is complete there’s a very special test on Monday 14 July. The rookie test returns for another year, giving motorsport’s biggest talents the chance to sample the fastest-ever Formula E machinery. 

    What is the Berlin Rookie Test?

    The mandatory test sees all 11 teams field two ‘rookies’ – someone who hasn’t participated in an E-Prix before – to get behind the wheel of the GEN3 Evos for a six hour all-day test. It has become an annual event, with Formula E and its teams having a long history of providing talent, working their way up the motor racing ladder, equal opportunities in current racing machinery.

    This has also expanded over time, with the championship breaking new ground last year by hosting an all-women’s test during Pre-Season Testing in Jarama, Spain. There was also a Rookie Free Practice held in Jeddah, Saudi Arabia, ahead of the races earlier this season. 

    All 11 teams have now confirmed the talent that will be jumping into the cars during the Season 11 Berlin Rookie Test, with drivers that include the reigning F1 ACADEMY champion, recent FIA Formula 2 race winners, and a Formula 1 podium finisher. 

    Who is confirmed for the 2025 Berlin Rookie Test?

    Here is the full confirmed list of drivers for the Berlin Rookie Test: 

    Team

    Driver 

    Driver

    Andretti

    Jak Crawford 

    Frederik Vesti 

    CUPRA KIRO 

    Callum Voisin

    Bianca Bustamante

    DS PENSKE

    Nikita Bedrin

    Danil Kvyat

    Envision Racing

    Johnathan Hoggard 

    Zak O’Sullivan

    Jaguar TCS Racing

    Jamie Chadwick

    Leonardo Fornaroli

    Lola Yamaha ABT

    Alessandro Giusti

    Hugh Barter

    Mahindra Racing

    Dino Beganovic

    Kush Maini

    Maserati MSG Racing

    Théo Pourchaire

    Arthur Leclerc 

    NEOM McLaren

    Ella Lloyd

    Alex Dunne

    Nissan

    Abbi Pulling 

    Gabriele Minì

    TAG Heuer Porsche

    Ayhancan Güven 

    Elia Weiss

     

    The Rookie Tests have been a proven pathway to Formula E too, with the likes of current championship contender Taylor Barnard (NEOM McLaren), multi-race winner Nick Cassidy (Jaguar TCS Racing), Jake Hughes (Maserati MSG Racing) Max Guenther (DS PENSKE) and former champ Nyck de Vries (Mahindra Racing) all graduating from rookie tests into full-time seats. 

    Andretti 

    Andretti Formula E team’s Reserve and Development Driver Jak Crawford returns to the Andretti Porsche 99X Electric cockpit for his third outing with the team in Berlin. The American recently won the Formula 2 Feature Race in Silverstone, and will now switch his focus to the Antretti team for the Berlin race weekend. 

    Joining him in Berlin is Danish talent Frederik Vesti, who will return to the all-electric World Championship having previously tested for Mahindra Racing at last year’s Rookie Test. A multiple race winner in Formula 2 and a former title contender, Vesti brings added pedigree through his role as a test and reserve driver for the Mercedes-AMG F1 team.

    CUPRA KIRO 

    Last month, CUPRA KIRO signed Bianca Bustamante as their official Development Driver. The Filipino talent raced in W Series before joining F1 Academy, and after securing two victories and a total of five podiums in a highly competitive field, Bianca has stepped up to the hotly contested GB3 Championship for 2025. She was on the ground in Jakarta for Dan Ticktum’s maiden Formula E victory, and has previous Formula E experience after representing NEOM McLaren and setting the third-fastest time in Formula E’s Women’s Test at Jarama in 2024.

    She will be joined by 2023 GB3 champion, Callum Voisin, who will get his first taste of Formula E. Since last year, the 19-year-old has raced in the FIA Formula 3 Championship and secured his maiden win in the series at the Circuit de Spa-Francorchamps, achieving a Grand Slam by claiming pole position and setting the fastest lap.

    DS PENSKE 

    Over at DS PENSKE, the team will be bringing back Danil Kvyat for the day-long session. The former Formula 1 driver has taken part in rookie sessions before, at the Rookie Test in Berlin with then-NIO 333. The Russian also took the wheel of the DS E-TENSE FE25 during the FP0 session at the Jeddah Corniche Circuit earlier this season. 

    On the other side of the garage, they have signed Nikita Bedrin to the Penske Driver Development Programme. Bedrin is multiple winner in international karting competition, having made headlines by dominating the 2020 WSK Super Master Series. More recently, he captured his first FIA Formula 3 Sprint Race victory in 2024, confirming his potential at the highest levels of junior single-seater racing.

    Envision Racing 

    The Silverstone-based team, Envision Racing, will be bringing back Brit Zak O’Sullivan for the Berlin Rookie Test. He has played an important role to the team throughout Season 11, supporting them with simulator work and contributing valuable data between race weekends to aid drivers Sebastien Buemi and Robin Frijns.

    Johnathan Hoggard will be alongside him, with his racing CV including race victories and championship podiums in both British Formula 4 and Formula 3. His standout performances earned him the prestigious BRDC Young Driver of the Year Award, which included a Formula 1 test as part of the prize.

    Jaguar TCS Racing

    Reigning Teams’ World Champions Jaguar TCS Racing have drafted in Jamie Chadwick for more testing, having taken part in both the Women’s Test in Madrid and the Rookie Free Practice session in Jeddah this season alone. Three-time W Series champion Chadwick has enjoyed a successful 2025 racing in sportscars, in addition to making her Le Mans debut in June. She took victory in the European Le Mans Series events this season for IDEC Sport in the LMP2 class.

    J_TCS_Racing_Jamie_Chadwick_Rookietest_Berlin_070725_001

    In contrast, the Berlin rookie test will be the first time Leonardo Fornaroli has driven Formula E machinery. The Italian is currently fourth in the FIA Formula 2 standings after taking his first victory of the season in Silverstone, and has a further four podiums and two pole positions so far in 2025 for Invicta Racing.

    Lola Yamaha ABT 

    Representing Lola Yamaha ABT is Alessandro Giusti, with 18-year-old Giusti making his debut in Formula E machinery when he jumps into the GEN3 Evo at the test. He has had an impressive junior career to-date, making his debut in the French F4 Championship in 2021 before winning the series in 2022 and then joining the Williams Racing Driver Academy in 2024. Giusti is currently competing in the FIA Formula 3 Championship.

    Australian-Japanese driver Hugh Barter will complete the line-up and return to Formula E, having previously competed in the Berlin Rookie Test in 2023. As Lola Yamaha ABT’s Simulator Test Driver, Barter has worked closely with the team, helping to optimise car setup and strategy, and will now be able to build upon his on-track experience.

    Mahindra Racing

    Kush Maini will return to Mahindra Racing for the Berlin Rookie Test, with the Indian widely impressing the paddock when he set the benchmark time under the lights in a dedicated Rookie Free Practice session in Jeddah, Saudi Arabia; his first taste of the Mahindra M11Electro and Formula E’s GEN3 Evo era.

    1751534622-kush maini formula e testing for mahindra

    The team will also call upon Dino Beganovic, a standout name on the FIA’s single-seater pathway for emerging talent in recent seasons. The 21-year-old is a race winner and championship contender through his stints in Formula 4, Formula Regional and FIA Formula 3, and currently competes in FIA Formula 2.

    Maserati MSG Racing 

    Maserati MSG Racing welcomes back Théo Pourchaire to the team, with the 2023 Formula 2 Champion previously taking part during the FP0 session in Jeddah earlier this season. “Formula E is such a unique and challenging championship,” Pourchaire said on the news, “I’m grateful for the opportunity to get more seat time and continue learning in this environment.”

    He’ll be joined by Monégasque native Arthur Leclerc, who rejoins the team having been part of the family during the team’s time as Venturi Racing. Leclerc originally joined the team as a Development Driver in 2017, progressing to Test and Reserve Driver roles for the 2019-2020 season. He also participated in the Rookie Test in Marrakesh in 2019.

    NEOM McLaren 

    As the Reserve and Development Driver for the NEOM McLaren team across Season 11, Alex Dunne will also take part in the Berlin Rookie Test for the team. The Irishman has caught the attention of racing fans during his stints in FIA Formula 2 this season, winning in Imola and Sakhir and currently sits third in the drivers’ standings. 

    Dunne-McLaren-rookie

    Ella Lloyd will also participate in the test, having joined the McLaren Driver Development Programme in October 2024. This year she is racing in F1 Academy season, and has already secured a race victory in Jeddah, and put 67 points on the board. Alongside her F1 Academy programme, Ella is also competing in her second season of British F4.

    Nissan 

    Abbi Pulling will return to Nissan, with the reigning F1 Academy champion finishing top of the timesheets at the all-women’s session in Jarama last November. This will be her first on-track appearance with the Japanese outfit in her new role as Nissan’s Rookie and Simulator Driver. The British racer is currently competing in the GB3 Championship, where she scored a strong fifth on debut at Silverstone earlier this season. 

    Formula 2 racer Gabriele Minì is also back, thanks to Nissan Formula E Team’s collaboration with Alpine Racing.The Italian driver will be looking to develop the skills he learned in his previous two outings in a Formula E car, having taken a top-10 finish in last year’s Berlin Rookie Test, before securing an impressive second in FP0 in Jeddah.

    TAG Heuer Porsche

    Finally, TAG Heuer Porsche have called up the youngest-ever Formula E driver for the Berlin Rookie Test. Sixteen-year-old Elia Weiss was born in 2009, and has been given the licence required to drive the highly efficient 99X Electric in Berlin. Weiss is one of Germany’s promising young racing drivers and is following in World Champion Pascal Wehrlein’s footsteps, as he is part of Motorsport Team Germany.

    319215_1920x1280

    Joining him will be Ayhancan Güven, who made it into the Porsche squad in 2020 when he was selected for the factory junior team. He currently races for Manthey EMA in the DTM. Earlier this year at Oschersleben and in Zandvoort, he secured his first two DTM victories in the Porsche 911 GT3 R.

    SCHEDULE: Where, when and how to watch or stream the 2025 Berlin E-Prix Rounds 13 & 14

    Berlin maintains its accolade of being the only city to be present on the calendar since the very first season. This time racing is set to run Saturday 12 and Sunday 13 July, as the first of two European double headers to close out Season 11.

    Make sure you’ve secured your tickets for this unmissable weekend!

    Find out more

    CALENDAR: Sync the dates and don’t miss a lap of Season 11

    WATCH: Find out where to watch every Formula E race via stream or on TV in your country

    TICKETS: Secure your grandstand seats and buy Formula E race tickets

    SCHEDULE: Here’s every race of the 2024/25 Formula E season

    HIGHLIGHTS: Catch up with every race from all 10 seasons of Formula E IN FULL

    PREDICTOR: Get involved, predict race results and win exclusive prizes

    HOSPITALITY: Experience Formula E and world class motorsport as a VIP

    FOLLOW: Download the Formula E App on iOS or Android

     

    Continue Reading

  • Platelet-Rich Plasma Therapy for Infertility Due to Premature Ovarian

    Platelet-Rich Plasma Therapy for Infertility Due to Premature Ovarian

    Introduction

    Infertility, defined as the inability to conceive following 12 months of consistent unprotected sexual activity, affects approximately 15% of couples worldwide and can lead to significant psychological and social consequences.1 The World Health Organization (WHO) reports that female infertility accounts for 37% of cases, male factors 8%, and both partners in 35%. Among women, ovulatory disorders, endometriosis, pelvic adhesions, tubal blockages, and hyperprolactinemia are frequent causes.2

    The European Society of Human Reproduction and Embryology (ESHRE) defines primary ovarian insufficiency (POI) refers to the loss of ovarian function before age 40, characterized by menstrual disturbances (amenorrhea or oligomenorrhea for at least 4 months) and persistently elevated follicle-stimulating hormone (FSH) levels (>25 IU/L on two occasions at least 4 weeks apart).3,4 Unlike menopause, POI may allow intermittent ovulation. The prevalence of POI rises with age, affecting approximately 1% of women by age 40. POI may be spontaneous or induced by medical interventions such as surgery, chemotherapy, or radiation.

    Ovarian failure can be classified as primary, due to intrinsic ovarian dysfunction (eg, surgical removal, hereditary disorders), or secondary, due to disruption in hormonal signalling from the hypothalamus or pituitary gland.5 Management guidelines from ESHRE) guidelines, emphasise a comprehensive, multidisciplinary approach to POI, including hormone replacement therapy (HRT) until the average age of natural menopause, fertility counselling, and monitoring for long-term health risks.3,4

    Despite various assisted reproductive technology (ART) methods, a significant proportion of embryo implantation attempts remain unsuccessful. Platelet-rich plasma (PRP) therapy is emerging as a promising adjunct treatment for patients with diminished ovarian reserve, including those with POI. Derived from autologous blood with platelet concentrations 4–5 times higher than baseline, PRP contains multiple cytokines and growth factors such as vascular endothelial growth factor (VEGF), transforming growth factor (TGF), platelet-derived growth factor (PDGF), and epidermal growth factor (EGF), which may stimulate ovarian tissue regeneration and improve ovarian function.6

    Current guidelines for the management of in vitro fertilization (IVF) and embryo transfer focus on maximizing success rates while minimizing risks such as multiple pregnancies and ovarian hyperstimulation syndrome (OHSS). PRP has been investigated not only for ovarian rejuvenation but also for improving endometrial thickness and implantation rates in cases of thin endometrium. Early studies suggest PRP enhances pregnancy outcomes by promoting a more receptive uterine environment.6

    This case series evaluates the effects of intraovarian PRP therapy on ovarian reserve markers and pregnancy outcomes in two women diagnosed with POI undergoing in vitro fertilization (IVF).

    Case Illustration

    Patient Selection and PRP Preparation

    This case series illustrates two patients with a history of infertility who underwent intraovarian PRP therapy followed by IVF. Both patients included in this case series fulfilled the diagnostic criteria for POI as defined by the ESHRE. These criteria include: age under 40 years, menstrual disturbance (oligomenorrhea or amenorrhea) for at least four months, and elevated follicle-stimulating hormone (FSH) levels >25 IU/L on at least two occasions. In both cases, AMH levels were significantly reduced (<1 ng/mL), and antral follicle count (AFC) was low. Neither patient had undergone bilateral oophorectomy nor had a history of exposure to gonadotoxic agents. Patients were selected for intraovarian PRP therapy based on spontaneous POI diagnosis, absence of identifiable secondary causes such as autoimmune disorders or chromosomal abnormalities, and their eligibility for IVF. Individuals with POI due to surgical causes, prior chemotherapy or radiotherapy, active pelvic infection, or uterine anomalies were excluded.

    PRP was prepared using the T-Lab autologous kit, involving 20–60 mL peripheral blood centrifuged to yield 4–8 mL PRP with platelet concentrations around 900,000/µL. PRP was injected intraovarian under sedation, 2–4 mL per ovary, administered twice per patient with sessions spaced one month apart. The PRP was used within two hours of preparation.

    Case 1

    Patient Characteristics

    A 25-year-old nulliparous woman with a history of ectopic pregnancy in 2021 and right salpingectomy presented to our IVF clinic with infertility concerns. Physical examination was normal, with a BMI of 25.53 kg/m². Initial laboratory tests indicated low AMH at 0.36 ng/mL (normal range: 1.0–4.0 ng/mL), elevated FSH at 13.3 mIU/mL (normal range for Day 2–3 of the menstrual cycle: 2.5–10.2 mIU/mL), and low luteinizing hormone (LH) at 2.48 mIU/mL (normal range: 1.9–12.5 mIU/mL). Transvaginal ultrasound performed on the second day of menstruation revealed an AFC of 2, with one follicle in each ovary (normal range for good ovarian reserve: 6–10 follicles per ovary). Hysterosalpingography indicated a non-patent right tube but a patent left tube. The husband’s semen analysis indicated teratozoospermia. Despite her regular menstrual history, her low AMH, high FSH, and low AFC indicated diminished ovarian reserve, meeting the criteria for POI per ESHRE guidelines. Consequently, ovarian PRP therapy was considered before IVF to enhance her ovarian response.5

    PRP Intervention

    The PRP was prepared using a T-Lab autologous platelet-rich plasma kit. Peripheral blood volumes of 40–60 mL were drawn per session, yielding 6–8 mL of PRP after centrifugation and extraction from the buffy coat layer. The platelet concentration was approximately 900,000/µL. Intraovarian PRP injections were administered under conscious sedation, with 2–4 mL injected per ovary. The patient underwent two PRP sessions spaced one month apart. After the first session, AMH increased to 0.46 ng/mL, FSH rose to 18.09 mIU/mL, and LH increased to 3.23 mIU/mL. Following the second session, AMH further increased to 0.63 ng/mL, and FSH decreased to 2.63 mIU/mL. PRP was prepared fresh for each session, using 20 mL of peripheral blood per procedure, with injections performed within two hours of preparation to maintain viability.

    IVF Outcome

    Patient received growth hormone, DHEA, folic acid, and vitamin D3 for 3 months before IVF stimulation. Controlled ovarian stimulation began on the third day of menstruation with clomiphene citrate for five days, followed by recombinant FSH (300 IU) and LH (150 IU). Cetrorelix acetate (0.25 mg) was administered from day 8. Growth hormone was continued daily until oocyte retrieval. Four oocytes were retrieved from four follicles, yielding one high-quality blastocyst that was cryopreserved. A frozen embryo transfer performed on August 6, 2023, resulted in a positive beta-hCG (547.26 mIU/mL) and ultrasound-confirmed fetal heartbeat, culminating in a successful pregnancy and live birth. Figures 1 and 2 shows an IVF Stimulation Chart Case 1. Figure 3 showed a blastocyst embryo was on good quality in case 1.

    Figure 1 IVF Stimulation Chart Case 1.

    Figure 2 The Frozen-embryo-transfer (FET) chart Case 1.

    Figure 3 The blastocyst embryo was on good quality in the first case-patient (A) thawing (B) assisted hatching.

    Case 2

    Patient Characteristics

    A 36-year-old nulliparous woman, married for seven years, presented with infertility. Her physical examination was normal, with a BMI of 27.38 kg/m². Laboratory evaluation revealed a low AMH of 0.25 ng/mL, elevated FSH of 18.52 mIU/mL, and low LH of 1.88 mIU/mL. Hysterosalpingography demonstrated bilateral tubal blockage. Transvaginal ultrasound on day 2 of menstruation showed an AFC of 3 (one follicle in the right ovary, two in the left), below the normal range of 6–10 follicles per ovary. The husband’s semen analysis indicated severe oligoteratozoospermia. The patient’s hormonal profile and ultrasound findings met the ESHRE diagnostic criteria for POI, characterized by hypergonadotropic hypogonadism. Given her history of regular menstruation earlier in life, secondary amenorrhea consistent with POI was diagnosed.

    PRP Intervention

    The patient received two ovarian PRP treatments administered between days 7 and 12 of the menstrual cycle. Each session involved drawing 20 mL of peripheral blood, centrifuged for 15 to 30 minutes to yield 4 mL of PRP from 10 mL of blood. The PRP was injected intraovarian within two hours of preparation. Following the first PRP treatment, AMH improved to 0.65 ng/mL, FSH decreased to 15.26 mIU/mL, and LH increased to 4.89 mIU/mL. After the second session, AMH rose further to 0.71 ng/mL, and FSH decreased to 8.52 mIU/mL.

    IVF Outcome

    Patient received growth hormone, DHEA, folic acid, and vitamin D3 for 3 months before IVF stimulation. Controlled ovarian stimulation began on the second day of menstruation with clomiphene citrate for five days, followed by recombinant FSH (300 IU) and LH (150 IU). Cetrorelix acetate (0.25 mg) was given starting day 7. Growth hormone administration continued daily until oocyte retrieval. Three oocytes were collected from four follicles, resulting in one high-quality blastocyst that was frozen. Frozen embryo transfer on May 31, 2023, led to a positive beta-hCG (187.08 mIU/mL) and confirmed fetal heartbeat on ultrasound, though the patient later experienced early pregnancy loss. Figures 4 and 5 shows the Frozen-embryo-transfer (FET) chart while Figure 6 shows a blastocyst embryo was on good quality in case 2.

    Figure 4 The Frozen-embryo-transfer (FET) chart Case.

    Figure 5 IVF Stimulation Chart Case 2.

    Figure 6 The blastocyst embryo was on good quality in the second case-patient (A) thawing (B) assisted hatching.

    Discussion

    POI affects 10–28% of cases primary amenorrhea and 4–18% of secondary amenorrhea, with significant psychological as well as physical impacts on affected women.7 Premature ovarian insufficiency (POI) is marked by disrupted folliculogenesis, which may present as a decreased follicle pool, increased follicular atresia, or defective recruitment mechanisms. These abnormalities contribute to a significantly reduced ovarian reserve and are a major cause of infertility in affected individuals.7–9

    The pregnancy rate in POI patients remains low (5–10%), despite advances in reproductive technologies, and traditional treatments such as ovarian stimulation protocols, androgen supplementation, and novel approaches like stem cell therapy or ovarian tissue autotransplantation have shown limited success. Recently, autologous platelet-rich plasma (PRP) ovarian injections have emerged as a promising therapeutic approach. PRP, rich in growth factors and cytokines such as VEGF, IGF, PDGF, and TGF-β, promotes angiogenesis, tissue regeneration, and cellular proliferation, potentially rejuvenating ovarian tissue and improving function.3 Concentrating cytokines and growth factors in PRP and injecting them directly into ovarian tissue is expected to improve ovarian function. Several prior studies reported increased ovarian angiogenesis, folliculogenesis, improved menstrual cycles, and improved ovarian function after PRP injection.3 Several studies have evaluated autologous PRP as proven to increase success in some cases of infertility.10–12

    In this report, we present two cases of POI patients treated with repeated intraovarian PRP injections followed by IVF stimulation. Both patients underwent standardized controlled ovarian stimulation protocols after PRP therapy, leading to the retrieval of oocytes, successful blastocyst formation, and positive pregnancy outcomes. Our findings align with previous studies demonstrating PRP’s potential to increase AMH levels, reduce FSH, enhance folliculogenesis, and improve pregnancy rates in women with diminished ovarian reserve (DOR).13,14

    Treatment Approaches

    Autologous PRP is derived by drawing a person’s blood from a peripheral vein, which is then centrifuged to eliminate red blood cells. This process aims to produce a concentrated platelet sample with growth factor levels 5 to 10 times higher than those released by activated platelets. The typical PRP preparation involves collecting whole blood, an initial centrifugation to separate and remove red blood cells, followed by another centrifugation to concentrate the platelets, and finally, adding a platelet agonist to activate the sample.11,15

    A post-PRP assessment was conducted to evaluate the parameters of AMH, FSH, and AFC. Stimulation is performed for the IVF program if it shows improvement. Following Farimani et al’s research involving 19 participants, it was found that the average number of oocytes before and after PRP injection was 0.64 and 2.1 respectively. Two patients experienced spontaneous pregnancy. The third case achieved clinical pregnancy and delivered a healthy baby. In cases of difficulty getting pregnant due to ovarian dysfunction, action is taken to inject PRP into both ovaries. The effect of PRP is increasing the number of ovarian oocytes, especially in women with poor ovarian reserve and POI, autologous intraovarian PRP therapy increases AMH levels and decreases FSH concentrations, with a trend of increasing live birth rates.16

    Similar effects were also found in women with chronic endometritis and recurrent implantation failure. Case of a 35-year-old woman with POI, six failed attempts after embryo transfer. The patient underwent FET of two blastocysts and succeeded in getting pregnant with twins. Four weeks after a positive β-hCG pregnancy test, clinical pregnancy was confirmed by observing fetal cardiac activity on transvaginal ultrasound. Twins were born at 36 weeks gestation with body weights of 2.28 kg and 2.18 kg.17

    PRP comprises many growth factors involved in the pathophysiology of ligament restoration, including VEGF, IGF-I, PDGF, hepatocyte growth factor (HGF), Transforming Growth Factor Beta (TGF-β), and Fibroblast Growth Factor (FGF).18 The primary benefits associated with the utilization of platelet-rich plasma (PRP) include its inherent autologous properties, absence of immunological responses and potential transmission of germs from the donor, its straightforward and expeditious preparation process (about 30 minutes from blood collection to application), and its cost-effectiveness However, it’s important to note that PRP therapy is contraindicated for patients with coagulation abnormalities, breastfeeding or pregnant women, individuals with cancer, active infections, and those on long-term use of non-steroidal anti-inflammatory drugs (NSAIDs).17

    In a prospective study by Cakiroglu et al, intraovarian injection of autologous platelet-rich plasma (PRP) was found to enhance ovarian response to stimulation and improve in vitro fertilization (IVF) outcomes in women diagnosed with primary ovarian insufficiency (POI). In this cohort, following PRP administration, 23 women (7.4%) achieved spontaneous conception, 201 women (64.8%) developed antral follicles and proceeded to IVF, while 87 women (27.8%) did not form antral follicles and, thus, received no further intervention. However, this study utilized only a single PRP injection without any follow-up interventions until conception was achieved.19

    The current study builds upon this by evaluating the effects of multiple PRP injections in POI patients, allowing us to assess whether repeated treatments lead to improved ovarian function and clinical outcomes. The presentation of these cases typically involved amenorrhea and low serum estrogen levels with elevated gonadotropins, consistent with POI diagnosis. Over the course of treatment, we observed variable responses to repeated PRP injections, with some patients demonstrating sustained follicular development and improved ovarian reserve markers, while others had limited responses.

    The two cases in this series exhibited distinct baseline characteristics, including differences in age, ovarian reserve markers (such as AMH and FSH), and duration of amenorrhea, which likely influenced their respective responses to repeated PRP injections and IVF outcomes. Younger patients with relatively higher AMH levels and shorter duration of amenorrhea tended to show more robust follicular development and better clinical responses, consistent with existing evidence that age and ovarian reserve are key predictors of fertility treatment success in POI. Conversely, patients with more advanced age and lower baseline ovarian reserve demonstrated more modest improvements, underscoring the heterogeneity of POI and the need for individualized treatment protocols.20 Understanding these patient-specific factors is crucial in interpreting clinical outcomes and optimizing PRP therapy for ovarian rejuvenation.

    Comparing our findings with the initial Cakiroglu study and other case reports in the literature, which primarily focus on single PRP administrations,19,21,22 our study suggests that multiple PRP injections may offer a more sustained benefit in follicular activation and ovarian responsiveness. This approach could potentially shift the clinical management of POI by introducing a novel protocol for ongoing ovarian stimulation and improving IVF outcomes for patients with diminished ovarian reserve.

    According to standard operational procedure for PRP injection in our fertility clinic, PRP injection is administered when the AMH level falls below 0.5 ng/mL, indicating an inadequate ovarian reserve.17,19,23,24 AMH levels less than 0.5 ng/mL is predictive of reduced success in management of infertility, therefore the target of AMH >0.5 ng/mL is crucial.25 The choice to administer numerous PRP injections was made since case 1 had a low AMH level (<0.5 ng/mL) after 1 month of follow-up, and case 2 had a low AMH level (<0.5 ng/mL) after 3 months of follow-up.

    Despite the promising observations in this case series, several limitations should be considered. The small sample size of only two patients restricts the generalizability of our findings and limits the ability to draw definitive conclusions about the efficacy of repeated PRP injections. Moreover, as a case series without a control group, it is difficult to exclude the possibility that clinical improvements may be influenced by confounding factors or natural variations in ovarian function. Variability in individual responses to IVF and PRP treatment further complicates interpretation. Larger, controlled studies with longer follow-up are needed to confirm these preliminary findings and to establish standardized treatment protocols.

    To best of our knowledge, no prospective or randomized controlled trials have evaluated the impact of numerous platelet-rich plasma injections on primary ovarian insufficiency in women undergoing in vitro fertilization. Furthermore, there was a lack of established standard protocol for PRP injection in patients with POI. From this case series, we can infer that the timing of the second ovarian PRP injection may also influence the result of pregnancy. Additional research with a prospective approach, involving a large population and multiple centers, is necessary.

    Conclusion

    Platelet-rich plasma (PRP) treatment represents a promising therapeutic approach to enhance ovarian reserve and improve reproductive outcomes in patients with primary ovarian insufficiency (POI), especially those preparing for in vitro fertilization (IVF). Our case series suggests that repeated PRP injections, particularly the timing of the second injection, may influence clinical pregnancy outcomes. However, due to the limited sample size and observational nature of this study, further prospective research with larger cohorts and standardized protocols is essential to validate these findings and clarify the impact of PRP on key clinical endpoints such as pregnancy rates, live birth rates, and ovarian function recovery.

    Informed Consent Patient Statement

    No formal ethical clearance was required for the publication of this case. The authors confirm that written informed consent for publication of this case report and any accompanying images was obtained from the patient and her spouse. The patient was informed in detail about the case content and agreed to its publication. All personal identifiers have been removed to ensure patient anonymity.

    Disclosure

    The authors report no conflicts of interest in this work.

    References

    1. Carson SA, Kallen AN. Diagnosis and Management of Infertility: a Review. JAMA. 2021;326:65–76. doi:10.1001/jama.2021.4788

    2. Walker MH, Tobler KJ. Female infertility. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.

    3. Tülek F, Kahraman A. The effects of intra-ovarian autologous platelet rich plasma injection on IVF outcomes of poor responder women and women with premature ovarian insufficiency. J Turk Ger Gynecol Assoc. 2022;23:14–21. doi:10.4274/jtgga.galenos.2021.2021.0134

    4. Chon SJ, Umair Z, Yoon MS. Premature ovarian insufficiency: past, present, and future. Front Cell Develop Biol. 2021;9:672890. doi:10.3389/fcell.2021.672890

    5. Webber L, Davies M, Anderson R, et al. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31:926–937.

    6. Allahveisi A, Seyedoshohadaei F, Rezaei M, Bazrafshan N, Rahimi K. The effect of platelet-rich plasma on the achievement of pregnancy during frozen embryo transfer in women with a history of failed implantation. Heliyon. 2020;6:e03577. doi:10.1016/j.heliyon.2020.e03577

    7. Gupta A, Tiwari P. Premature ovarian insufficiency: a review. EMJ Reprod Health. 2019;5.

    8. Federici S, Rossetti R, Moleri S, et al. Primary ovarian insufficiency: update on clinical and genetic findings. Front Endocrinol. 2024;15:1464803.

    9. Flatt SB, Baillargeon A, McClintock C, Pudwell J, Velez MP. Premature ovarian insufficiency in female adolescent and young adult survivors of non-gynecological cancers: a population-based cohort study. Reprod Health. 2023;20:4. doi:10.1186/s12978-022-01559-8

    10. Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. Int J Mol Sci. 2020;22:21. doi:10.3390/ijms22010021

    11. TKC V, Tanaka Y, Kawamura K. Ovarian rejuvenation using autologous platelet-rich plasma. Endocrines. 2021;2:15–27. doi:10.3390/endocrines2010002

    12. Pacu I, Zygouropoulos N, Dimitriu M, Rosu G, Ionescu CA. Use of platelet-rich plasma in the treatment of infertility in poor responders in assisted human reproduction procedures. Exp Ther Med. 2021;22:1412. doi:10.3892/etm.2021.10848

    13. Penzias A, Bendikson K, Butts S. Guidance on the limits to the number of embryos to transfer: a committee opinion. Fertil Steril. 2021;116:651–654. doi:10.1016/j.fertnstert.2021.06.050

    14. Tong Y, Cheng N, Jiang X, et al. The Trends and Hotspots in Premature Ovarian Insufficiency Therapy from 2000 to 2022. Int J Environ Res Public Health. 2022;20:19. doi:10.3390/ijerph20010019

    15. Atkinson L, Martin F, Sturmey RG. Intraovarian injection of platelet-rich plasma in assisted reproduction: too much too soon? Hum Reprod. 2021;36:1737–1750. doi:10.1093/humrep/deab106

    16. Farimani M, Heshmati S, Poorolajal J, Bahmanzadeh M. A report on three live births in women with poor ovarian response following intra-ovarian injection of platelet-rich plasma (PRP). Molecular Biology Reports. 2019;46:1611–1616. doi:10.1007/s11033-019-04609-w

    17. Streit-Ciećkiewicz D, Kołodyńska A, Futyma-Gąbka K, Grzybowska ME, Gołacki J, Futyma K. Platelet rich plasma in gynecology-discovering undiscovered-review. Int J Environ Res Public Health. 2022;20:19.

    18. Wen YH, Lin WY, Lin CJ, et al. Sustained or higher levels of growth factors in platelet-rich plasma during 7-day storage. Clin Chim Acta. 2018;483:89–93. doi:10.1016/j.cca.2018.04.027

    19. Cakiroglu Y, Saltik A, Yuceturk A, et al. Effects of intraovarian injection of autologous platelet rich plasma on ovarian reserve and IVF outcome parameters in women with primary ovarian insufficiency. Aging. 2020;12:10211–10222. doi:10.18632/aging.103403

    20. Wang Y, Jiang J, Zhang J, Fan P, Xu J. Research progress on the etiology and treatment of premature ovarian insufficiency. Biomed Hub. 2023;8:97–107. doi:10.1159/000535508

    21. Aflatoonian A, Lotfi M, Saeed L, Tabibnejad N. Effects of intraovarian injection of autologous platelet-rich plasma on ovarian rejuvenation in poor responders and women with primary ovarian insufficiency. Reprod Sci. 2021;28:2050–2059. doi:10.1007/s43032-021-00483-9

    22. Hsu CC, Hsu L, Hsu I, Chiu YJ, Dorjee S. Live birth in woman with premature ovarian insufficiency receiving ovarian administration of Platelet-Rich Plasma (PRP) in combination with gonadotropin: a case report. Front Endocrinol. 2020;11:50. doi:10.3389/fendo.2020.00050

    23. Zadehmodarres S, Salehpour S, Saharkhiz N, Nazari L. Treatment of thin endometrium with autologous platelet-rich plasma: a pilot study. JBRA Assisted Reprod. 2017;21:54–56. doi:10.5935/1518-0557.20170013

    24. Jankowska K. Premature ovarian failure. Przeglad menopauzalny. 2017;16:51–56. doi:10.5114/pm.2017.68592

    25. Ishrat S, Banu J, Deeba F, Salam S, Saha C, Akhtar A. Ovarian function following intra-ovarian injection of platelet rich plasma in premature ovarian aging. Int J Reprod Contracept Obstet Gynecol. 2022;11:1835.

    Continue Reading

  • Samsung Introduces Future-Ready Mobile Security for Personalized AI Experiences – Samsung Newsroom South Africa

    Samsung Introduces Future-Ready Mobile Security for Personalized AI Experiences – Samsung Newsroom South Africa

    New innovations including Knox Enhanced Encrypted Protection, updated Knox Matrix threat response and quantum-resistant Secure Wi-Fi strengthen privacy and user control for upcoming Galaxy smartphones

    Samsung Electronics Co., Ltd. today announced a new set of security and privacy updates rolling out with its upcoming Samsung Galaxy smartphones with One UI 8. These updates reinforce Samsung’s commitment to delivering powerful, trusted mobile technology in a rapidly evolving digital world by introducing new protections for on-device AI, expanding cross-device threat detection and enhancing network security with quantum-resistant encryption.

     

    Next-Generation Mobile Security for AI Personalization

    Samsung is introducing,[1] a new architecture designed to safeguard the next generation of personalized, AI-powered features, as its latest innovation in mobile security. KEEP creates encrypted, app-specific storage environments within the device’s secure storage area, ensuring that each app can access only its own sensitive information and nothing more.

     

    Supporting Galaxy’s Personal Data Engine (PDE),[2] KEEP helps secure a user’s deeply personal insights – such as routines and preferences – that enable features like Now Brief and Smart Gallery search. These insights stay entirely on-device, protected by KEEP and further secured by Knox Vault, Samsung’s tamper-resistant hardware security environment. The result is a seamless foundation for Galaxy AI that delivers personalized intelligence while keeping data tightly contained and under the user’s control.

    KEEP’s system-level structure allows it to scale across Galaxy AI innovations. In addition to PDE, it now protects Now Brief, Smart Suggestions and other on-device features that rely on user-specific inputs – enabling more advanced AI experiences without compromising privacy. With KEEP, Samsung is redefining how mobile devices safeguard data in the background to elevate privacy from a setting to an embedded design principle.

     

    Smarter, More Connected Threat Response with Knox Matrix

    As AI becomes more integrated across the ecosystem, Samsung is advancing protections that offer not just stronger security, but greater transparency and control for users, with Knox Matrix leading the way. Through One UI 8, Samsung is evolving Knox Matrix to deliver more proactive and user-friendly protection for connected Galaxy devices. When a device is flagged for serious risk – such as system manipulation or identity forgery – it is designed to automatically sign out of the Samsung Account, cutting off access to cloud-connected services to prevent threats from spreading.[3]

     

    Users are notified across their connected Galaxy devices and guided to the ‘Security status of your devices’ page, where they can review the issue and take action. Even devices without the latest security status updates trigger a yellow-level warning, helping users respond before vulnerabilities grow.

    Together, these updates make Samsung Galaxy’s ecosystem-level protection more dynamic, intuitive and visible, empowering users to maintain trust across all their devices with more confidence and clarity.

     

    Secure Wi-Fi Strengthened with Quantum-Resistant Encryption

    In continuation of its commitment to quantum-safe security, Samsung is bringing post-quantum cryptography to Secure Wi-Fi[4] extending the trusted approach first introduced on the Galaxy S25 series through Post-Quantum Enhanced Data Protection (EDP). Secure Wi-Fi is now being upgraded with a new cryptographic framework[5] designed to strengthen network protection against emerging threats, particularly those anticipated in the era of quantum computing. This enhancement secures the key exchange process at the core of encrypted connections, helping ensure robust privacy even over public networks.

     

    Quantum computing, once fully realized, could undermine many of today’s data protection methods. By integrating post-quantum cryptography, Secure Wi-Fi is built to withstand future attacks that capture encrypted data with the intent to break it once quantum technology matures – a tactic known as “harvest now, decrypt later.” This upgrade fortifies the secure tunnel between Galaxy devices and Samsung servers, reinforcing the integrity of data transmissions in high-risk environments like public Wi-Fi.

     

    In addition to this future-ready foundation, Secure Wi-Fi offers a suite of advanced privacy features:

    • Auto Protect: Automatically activates in public places like cafés, airports or hotels, securing Wi-Fi connections without requiring user action.
    • Enhanced Privacy Protection (EPP): Encrypts internet traffic and routes it through multiple layers, combining packet encryption and relay to anonymize device information and help prevent tracking.
    • Protection Activity: Provides visibility into protection history by showing which apps and networks were secured and how much data was encrypted over time.

     

    A Trusted Platform with Built-In Safeguards

    In addition to its latest innovations, Samsung continues to strengthen the core protections that underpin the Galaxy experience. These features reflect a multi-layered security approach that protects across hardware and software, while giving users greater visibility and control:

    • Knox Vault secures sensitive credentials such as passwords, PINs and biometrics in a physically isolated environment, helping to keep them protected even if the main operating system is compromised.
    • Auto Blocker helps provide defense by default, blocking unauthorized app installs, restricting command-based attacks and mitigating risks from potential zero-click threats.
    • Advanced Intelligence Settings gives users the option to turn off online data processing for AI features, so personal information can stay on-device, fully under their control.
    • Enhanced Theft Protection helps protect personal data even in high-risk situations such as robbery, using safeguards like Identity Check and Security Delay to prevent unauthorized access.

     

    This latest set of updates reinforces Samsung’s long-standing commitment to mobile security that evolves with innovation. It strengthens on-device privacy for personalized AI with , expands transparency and user control through Knox Matrix, and introduces quantum-resistant protection to Secure Wi-Fi for a more future-ready Galaxy experience. As new security challenges emerge, Samsung remains focused on delivering safeguards that are built in, always on and ready for what’s next.

    [1] Available on Galaxy smartphones and tablets with One UI 8 or later.

    [2] The Personal Data Engine functions when the Personal Data Intelligence menu is on. Analyzed data will be deleted once the Personal Data Intelligence menu is turned off.

    [3] Available on Galaxy smartphones and tablets with One UI 8 or later. Availability may vary by model and/or market.

    [4] Secure Wi-Fi offers free protection of up to 1024MB per month for Android OS 13 or later, and 250MB per month for Android OS 12 or earlier versions. Availability details may vary by market or network provider and connectivity is subject to applicable network environments.

    [5] This upgrade applies a post-quantum cryptographic algorithm certified under NIST FIPS 203 (ML-KEM). Availability may vary by market, model, and OS version.

    Continue Reading

  • Two crew hurt, two missing in attack on ship off Yemen; Houthis say they sunk Greek carrier – Reuters

    1. Two crew hurt, two missing in attack on ship off Yemen; Houthis say they sunk Greek carrier  Reuters
    2. Crew abandons cargo ship in Red Sea after drone, grenade attack  Al Jazeera
    3. Crew abandons Liberian-flagged, Greek-owned ship attacked in the Red Sea, UK military says  AP News
    4. Two dead in Houthi speedboat attack on cargo ship in Red Sea  The Guardian
    5. UN Chief Calls for Talks Amid New Red Sea Strikes  Mirage News

    Continue Reading

  • Keywords Studios Appoints Jonathan “JZ” Zweig as Chief Revenue Officer

    Elevating Global Collaboration and Value

    In his new role, Jonathan will lead a global function and work closely with Keywords’ studios and teams to align solutions with partner goals and enhance delivery through technology-enabled capabilities. His focus is on ensuring Keywords continues to provide meaningful value and remains a trusted global partner, with a deep understanding of both the creative process and the business of building IPs that inspire lasting fandom.

    Advancing the Keywords Mission

    Jonathan’s appointment supports Keywords Studios’ mission to help partners imagine more – whether that’s scaling a franchise, launching a new IP or finding smarter ways to bring ambitious creative visions to life.

    Jonathan Zweig commented:
    “Keywords Studios has built an impressive global presence with exceptional talent. This is a time of change across the industry, but also one full of possibility. I’m looking forward to working closely with our partners to support their goals, unlock new opportunities, and connect with fans in meaningful ways.”

    A Passion for Games

    A lifelong gamer, Jonathan can often be found playing Hearthstone and other favourite titles. He brings both extensive industry expertise and genuine passion to the role.

    Welcome aboard, JZ!


    Continue Reading

  • GLP-1s May Ease Symptom Burden in Patients With Fibromyalgia

    GLP-1s May Ease Symptom Burden in Patients With Fibromyalgia

    TOPLINE:

    The use of GLP-1 receptor agonists was linked to lower pain and fatigue in patients with fibromyalgia, according to a large-scale health records analysis.

    METHODOLOGY:

    • Researchers used the TriNetX database to identify patients with a diagnosis of fibromyalgia, with or without documented use of GLP-1s.
    • Used propensity score matching to form two patient cohorts (GLP-1 users vs nonusers), each consisting of 38,439 patients.
    • Assessed for documented opioid use and International Classification of Diseases, 10th Revision (ICD-10) codes for chronic pain, fatigue, and malaise.
    • Followed patients for 5 years, starting 1 year after their fibromyalgia diagnosis and initiation of GLP-1 medication.

    TAKEAWAY:

    • Patients with fibromyalgia who were taking GLP-1s were less likely to use opioids than the comparison group (47.3% vs 59.9%).
    • The GLP-1 group also had lower rates of reported fatigue, malaise, and pain.
    • Ongoing fibromyalgia care (defined by the presence of the ICD-10 code for fibromyalgia) was lower in the GLP-1 group (39.1%) than in the nonuser group (55.7%).
    • Additional research is needed using validated outcome measures like the Fibromyalgia Impact Questionnaire and Patient-Reported Outcomes Measurement Information System.

    IN PRACTICE:

    “The way that I use it in my practice these days is that if I have a patient with chronic pain or with fibromyalgia who has comorbidities that already have an FDA approval for GLP-1 use, such as obesity, diabetes, or obstructive sleep apnea, I would encourage them to go to their primary care physician and maybe consider getting started on a GLP-1,” said presenter Nouran Eshak, MB ChB, of the Mayo Clinic in Scottsdale, Arizona.

    SOURCE:

    This abstract was presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting in Barcelona, Spain.

    LIMITATIONS:

    This study had a retrospective design and relied on ICD-10 coding. Validated fibromyalgia-specific symptom scales or outcome measures were not available. Researchers were unable to account for confounders such as duration of illness, symptom severity, GLP-1 dosage, or access to healthcare.

    DISCLOSURES:

    The study authors disclosed having no relevant financial relationships.

    Continue Reading